Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Overview
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
Avantyx Pharmaceuticals LLC
Paradigm Biopharmaceuticals Ltd
Pharmahungary Group
SteroTherapeutics LLC
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Drug Profiles
Antisense Ri Oligonucleotides to Inhibit MMP-13 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit MMP-13 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Matrix Metalloproteise 13 (MMP-13) Inhibitors - Drug Profile
Product Description
Mechanism Of Action
History of Events
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Dormant Products
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Discontinued Products
Collagese 3 (Matrix Metalloproteise 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2022: MPS clinical program update and paradigm to present at the Intertiol Conference on lysosomal diseases
Jul 13, 2022: Paradigm partners with NFL Alumni Health on osteoarthritis program
Jul 06, 2022: Paradigm reports important global progress for the PARA_OA_002 phase 3 clinical trial evaluating Zilosul for osteoarthritis.
Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment
May 24, 2022: Paradigm Biopharmaceuticals spotlights potential breakthrough osteoarthritis treatment at Biological Association 3rd Annual Summit
May 05, 2022: Paradigm doses first subjects in Phase III knee osteoarthritis trial
Apr 13, 2022: FDA grants Fast Track Desigtion for Paradigm Biopharmaceuticals phase III osteoarthritis program
Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S
Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.
Feb 11, 2022: Intertiol researchers highlight the need for PPS as a new adjunct therapy treatment for unmet needs of patients with MPS VI
Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia
Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference
Dec 16, 2021: PPS treatment demonstrates improvement in heart function and tissue preservation in preclinical heart failure model
Nov 23, 2021: Positive interim data from phase 2 rare disease trial presented at intertiol medical congress
Nov 03, 2021: Paradigm’s Investigatiol New Drug (IND) application cleared by the US FDA.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aquilus Pharmaceuticals Inc, 2022
Pipeline by Avantyx Pharmaceuticals LLC, 2022
Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Pipeline by Pharmahungary Group, 2022
Pipeline by SteroTherapeutics LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022